title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
InnovationRx: Battle Of The AI Medical Scribes,20240515T203829,https://www.forbes.com/sites/katiejennings/2024/05/15/innovationrx-battle-of-the-ai-medical-scribes/,NVO,0.119038,Somewhat-Bullish,0.187627
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win - Biogen  ( NASDAQ:BIIB ) ,20220928T201722,https://www.benzinga.com/general/biotech/22/09/29061026/these-stocks-are-on-the-radar-after-biogen-eisais-surprising-alzheimers-trial-win,NVO,0.112269,Neutral,0.0
Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket,20220804T105117,https://www.benzinga.com/news/22/08/28349800/why-is-yellow-trading-higher-by-33-here-are-48-stocks-moving-premarket,NVO,0.08924,Neutral,0.0
"Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight",20240409T214100,https://www.prnewswire.com/news-releases/global-tissue-banking-market-to-exhibit-growth-at-a-considerable-cagr-of-6-by-2030-assesses-delveinsight-302110459.html,NVO,0.045962,Neutral,0.03774
"Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts DelveInsight",20240124T220100,https://www.prnewswire.com/news-releases/drug-eluting-balloons-global-market-is-expected-to-expand-at-a-healthy-growth-rate-of-8-by-2028-predicts-delveinsight-302042856.html,NVO,0.025985,Neutral,0.033663
"Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight",20240115T220500,https://www.prnewswire.com/news-releases/heart-failure-treatment-drug-market-to-accelerate-immensely-by-2032-predicts-delveinsight-302034593.html,NVO,0.046861,Neutral,0.08891
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress,20230801T110500,https://www.globenewswire.com/news-release/2023/08/01/2715661/0/en/uniQure-Announces-Second-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html,NVO,0.016304,Neutral,0.049953
Merck  ( MRK )  Begins Pivotal Studies on Four Cancer Candidates,20240108T151100,https://www.zacks.com/stock/news/2207014/merck-mrk-begins-pivotal-studies-on-four-cancer-candidates,NVO,0.267559,Neutral,0.057317
Here's Why You Should Invest in Adverum  ( ADVM )  Stock Now,20240104T132700,https://www.zacks.com/stock/news/2205527/heres-why-you-should-invest-in-adverum-advm-stock-now,NVO,0.209365,Neutral,0.055322
Here's Why You Should Bet on Rigel Pharmaceuticals  ( RIGL )  Now,20240103T155100,https://www.zacks.com/stock/news/2205099/heres-why-you-should-bet-on-rigel-pharmaceuticals-rigl-now,NVO,0.211806,Neutral,-0.001638
Here's Why You Should Invest in Aquestive  ( AQST )  Stock Now,20240103T131000,https://www.zacks.com/stock/news/2204853/heres-why-you-should-invest-in-aquestive-aqst-stock-now,NVO,0.164656,Neutral,-0.00136
Eli Lilly  ( LLY )  Stock Up 57% in 2023: Will the Uptrend Continue?,20240102T134300,https://www.zacks.com/stock/news/2204399/eli-lilly-lly-stock-up-57-in-2023-will-the-uptrend-continue,NVO,0.15347,Neutral,0.044317
Marinus  ( MRNS )  to Sell Rare Disease PRV to Novo Nordisk,20220715T154300,https://www.zacks.com/stock/news/1953027/marinus-mrns-to-sell-rare-disease-prv-to-novo-nordisk,NVO,0.192183,Somewhat-Bullish,0.315758
Jim Cramer's top 10 things to watch in the stock market Wednesday,20241204T141849,https://www.cnbc.com/2024/12/04/jim-cramers-top-10-things-to-watch-in-the-stock-market-wednesday.html,NVO,0.049629,Neutral,-0.098218
Incyte  ( INCY )  Receives FDA Approval for Skin Cancer Treatment,20230323T161400,https://www.zacks.com/stock/news/2069786/incyte-incy-receives-fda-approval-for-skin-cancer-treatment,NVO,0.151064,Neutral,0.062243
Provention  ( PRVB )  Skyrockets 260% on Buyout Offer From Sanofi,20230314T163200,https://www.zacks.com/stock/news/2065615/provention-prvb-skyrockets-260-on-buyout-offer-from-sanofi,NVO,0.262522,Neutral,0.100837
Microsoft  ( MSFT )  Q2 2023 Earnings Call Transcript,20230125T030031,https://www.fool.com/earnings/call-transcripts/2023/01/24/microsoft-msft-q2-2023-earnings-call-transcript/,NVO,0.0046,Neutral,0.118414
